Drug points: Dysgeusia and burning mouth syndrome by eprosartan

British Medical Journal

Volumn 325, Issue 7375, 2002, Pages 1277-

  Castells, Xavier ^a   Rodoreda, Isidre ^b   Pedrós, Consuelo ^a   Cereza, Gloria ^a   Laporte, Joan Ramon ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Area Basica de Salut Pla d'Urgell   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; LOSARTAN; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BURNING MOUTH SYNDROME; CASE REPORT; DRUG SURVEILLANCE PROGRAM; DYSGEUSIA; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; PRIORITY JOURNAL; TASTE DISORDER;

ACRYLATES; ANTIHYPERTENSIVE AGENTS; BURNING MOUTH SYNDROME; CASE REPORT; DYSGEUSIA; FEMALE; HUMAN; IMIDAZOLES; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0037202703     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Henkin RI. Drug-induced taste anti smell disorders. Incidence, mechanisms and management related primarly to treatment of sensory receptor dysfunction. Drug Saf 1994;11:318-77.
2. Mazzolai I., Burnier M. Comparative safety and tolerability of angiotensin II-receptor antagonists. Drug Saf 1999;21:23-33.
3. Malnick SD, Becker S. Dysgeusia by losartan in a patient intolerant of captopril. Med Gen Med 1999;4:E33.
4. Schlienger RG, Saxer MS, Haefeli WE. Reversible dysgeusia associated with losartan. Lancet 1996;347:471-2.
5. Heeringa M, van Puijenbroek EP. Reversible dysgeusia attributed to losartan. Ann Intern Med 1998;129:72.
6. Stroeder D, Zessig, I Heath R. Angiotensin-II antagonist cGP 48933 (Valsartan). Ergebnisse einer doppelblinden, plazebo-kontrolierten multicenter-studie. Nieren Hochdruckkrankheiten 1994;23:217-20.